Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025781
pages 183-217

Inhalational Drug Delivery in Pulmonary Aspergillosis

Ranjot Kaur
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014; School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom
Ripandeep Kaur
UGC Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014
Charan Singh
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014
Shahdeep Kaur
UGC Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014
Amit K. Goyal
Institute of Research and Development, Gujarat Forensic Science University, Gandhinagar, Gujarat, India 382007
Kamalinder K. Singh
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom
Bhupinder Singh
University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India 160014; UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India 160014

RÉSUMÉ

Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.


Articles with similar content:

Photosensitized Inactivation of Protozoa Pathogenic Agents of Water- and Vector-Borne Diseases
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 3
Laura Guidolin, Clara Fabris, Marina Soncin, Giulio Jori, Olimpia Coppellotti
Mycobacterium Tuberculosis Proteases and Implications for New Antibiotics Against Tuberculosis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 4
Jianping Xie, Quanju Zhao
Current Nanotechnological Strategies for Treating Glaucoma
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 5
Goutam Rath, Tarun Garg, Amit Kumar Goyal, Gagandeep Goyal
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Nanoparticle Drug Formulations for Cancer Diagnosis and Treatment
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Xuan Zhang , Jay Nadeau, Wilson Poon